WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
ADCelerate delivers Phase I appropriate antibody-drug conjugate (ADC) drug substance and drug product for Investigational New Drug (IND) submission
Plant is part of the company's CAD $30 million capital investment in the site
Brings 25 years of global operations and supply chain experience to Piramal
New block enhances the company's global capabilities in Oral Solid Dosage (OSD) Forms, increasing total plant capacity to 4.5 billion doses
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
Subscribe To Our Newsletter & Stay Updated